ADRB2 rs1042638: Understanding Your Genetic Variant
The rs1042638 variant is a common genetic polymorphism located within the ADRB2 gene, which provides instructions for making the beta-2 adrenergic receptor. This receptor plays a key role in the body's response to certain respiratory medications, leading researchers to study how this variant may influence individual responses to bronchodilator therapy.
What each genotype means
Arg16 homozygous genotype
This genotype results in the expression of the Arg16 variant of the beta-2 adrenergic receptor. Research suggests that this variant may be more susceptible to receptor downregulation following long-term exposure to beta-agonist medications, which could potentially attenuate the bronchodilator response in some individuals. Please discuss your asthma or COPD treatment plan and medication efficacy with your clinician or pharmacist.
Carried by approximately 16% of the population of European ancestry, with higher frequencies observed in other populations such as those of African ancestry.
Arg16/Gly16 heterozygous genotype
This genotype indicates you carry one copy of the Arg16 allele and one copy of the Gly16 allele. Studies on bronchodilator response show mixed results regarding how this combination influences medication efficacy compared to homozygous genotypes. Because individual responses to inhaled beta-agonists can vary significantly, you should consult your healthcare provider to determine if your current treatment is optimal for your needs.
This is the most common genotype, found in nearly half of the population across many studied ethnic groups.
Gly16 homozygous genotype
This genotype results in the expression of the Gly16 variant of the beta-2 adrenergic receptor. Some research indicates that individuals with this genotype may experience different bronchodilator responses compared to those with the Arg16 variant, though clinical evidence remains inconsistent across different populations. Always discuss your medication response and any concerns about your respiratory treatment with your doctor or pharmacist.
Carried by roughly 36% of the total population, though frequencies vary significantly by ancestry.
What is the rs1042638 Variant?
The rs1042638 variant is a single nucleotide polymorphism (SNP) found within the ADRB2 gene. In genetics, a SNP represents a variation at a single position in the DNA sequence. This specific variant is located in a region of the gene that influences the structure or regulation of the beta-2 adrenergic receptor. Because this receptor is a primary target for common inhaled medications used to treat conditions like asthma and chronic obstructive pulmonary disease (COPD), scientists have long investigated whether variations at this site might explain why some individuals respond differently to these treatments than others. It is important to note that while this variant is frequently studied, it is just one of many factors that can influence how a person's body interacts with medications.
The Role of the ADRB2 Gene
The ADRB2 gene encodes the beta-2 adrenergic receptor, a protein found on the surface of smooth muscle cells in the airways, as well as in other tissues throughout the body. When activated by signaling molecules or medications known as beta-agonists, these receptors trigger a cascade of events that cause the airway muscles to relax, which helps open the airways and improve breathing. Because this receptor is essential for the bronchodilator effect of many rescue inhalers, researchers have hypothesized that genetic differences in the receptor's structure could alter how effectively these drugs work. Variations in this gene have been studied for their potential to affect receptor stability, how the receptor is recycled by the cell, and how it responds to long-term exposure to medication.
Research and Evidence Strength
The evidence linking rs1042638 and other ADRB2 variants to clinical outcomes is considered moderate and often conflicting. While early studies suggested that specific genotypes might correlate with differences in bronchodilator response or asthma severity, subsequent large-scale meta-analyses and genome-wide association studies (GWAS) have often failed to replicate these findings consistently across diverse populations. Some research indicates that the effects of these variants may be influenced by other genetic factors or environmental conditions, making it difficult to draw definitive conclusions. Furthermore, some recent studies have reported a lack of significant association between common ADRB2 variants and treatment response in specific cohorts. Because of these mixed results, the clinical utility of testing for this variant remains a subject of ongoing scientific debate rather than a standard practice.
Population Frequency
The rs1042638 variant is considered a common polymorphism, meaning it is found at relatively high frequencies across many different human populations globally. Because it is common, most individuals will carry at least one copy of the variant, and it is not considered a rare mutation or a disease-causing variant in the traditional sense. Its prevalence means that it is a standard part of human genetic diversity, though the exact distribution of the specific alleles can vary depending on ancestral background. Researchers often account for these frequency differences when conducting studies to ensure that observed associations are not simply due to population structure.
What This Information Means for You
If you have information about your genotype for rs1042638, it is important to understand that this data is for educational purposes and should not be used to make medical decisions. Genetic variants are only one piece of a much larger puzzle that includes your overall health, environmental factors, and other genetic influences. You should never change your medication dosage or stop using a prescribed inhaler based on genetic test results. If you are curious about how your genetics might relate to your treatment, the best course of action is to discuss this with your clinician or a pharmacist. They can provide context based on your specific medical history and current clinical guidelines, ensuring that your treatment plan is safe and effective for your individual needs.
How common is this variant?
The rs1042638 variant is a common polymorphism found across diverse global populations, with its specific allele frequencies varying by ancestry.
Frequently asked questions
Can I use this genetic test to see if my asthma medication will work?
Currently, genetic testing for ADRB2 variants is not a standard clinical tool for predicting medication response. You should rely on your doctor's assessment of your symptoms and lung function tests rather than genetic data.
Is rs1042638 a disease-causing mutation?
No, rs1042638 is a common genetic variation, not a disease-causing mutation. It is part of the normal range of human genetic diversity.
Should I change my inhaler if I have a specific genotype?
Absolutely not. Never change or stop your prescribed medication without consulting your healthcare provider, as doing so could be dangerous for your respiratory health.
Why do different studies show different results for this variant?
Genetic associations can be complex and are often influenced by other genes, environmental factors, and the specific populations being studied. Inconsistent results are common in pharmacogenomics as researchers work to understand these complex interactions.
Sources & further reading
Educational information only, last refreshed 10/7/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs1042638?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in ADRB2
Variant in the beta-2 adrenergic receptor linked to metabolic regulation, exercise-induced lipolysis, and endurance performance.
Synonymous polymorphism in the beta-2 adrenergic receptor (Gln27Glu) modulating receptor down-regulation.
The Gln27Glu variant in the beta-2 adrenergic receptor is associated with metabolic and vascular responses to exercise.
Modulates beta-2 adrenergic receptor expression and cardiovascular reactivity.
This variant in the beta-2 adrenergic receptor gene is associated with differential responses to beta-agonist therapy in asthma patients.
Functional variant in the beta-2 adrenergic receptor linked to metabolic rate and cardiovascular reactivity.